Clareo Health | A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant (male or female) must be 18 years of age inclusive, at the time of signing the informed consent.
Histologically confirmed HCC or non-invasive diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria
Histologically or cytologically confirmed solid tumors
Child-Pugh class A and B7
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
Able to tolerate the study procedures, including 3 PET/CT scans
Adequate bone marrow, hepatic, and renal function
Agreed to take proper contraception measures
You may not be if
Impaired cardiac function or clinically significant cardiac disease (i.e., congestive heart failure New York Heart Association \[NYHA\] Class II, III or IV).
Patients with arterial thrombotic or embolic events or venous pulmonary embolism within 3 months before the start of study intervention.
On-going systemic anticancer therapy except continued luteinizing hormone-releasing hormone (LHRH) agonist or antagonists in participants with prostate adenocarcinoma
Administered a radioisotope within 9 physical half-lives of that radioisotope (24 days for yttrium-90 or 90Y) before administration of the study interventions
Any local or locoregional therapy of intrahepatic tumor lesions, open biopsy or significant traumatic injury \< 4 weeks before administration of the study interventions.
Known hypersensitivity to human monoclonal antibodies.
Any condition which, in the opinion of the Investigator, would preclude participation in this study.
